… The target-onset time windows for calculating the mean N2 and P3 amplitudes were between
… The pathology of PD is marked by a neurotransmitter (eg, dopamine) deficiency. In animal …

… therapeutic effect of dopaminergic treatments gradually diminishes with time. Exercise training,
… multiple neurotransmitter system disorders, cellular dysfunction and neuroinflammation. …

… enhances the survival of dopaminergic neurons, improves dopaminergic neurotransmission
and motor performance. Pharmacological therapies of PD are symptom-targeting, and their …

… survival of dopaminergic striatal neurons in patients with Parkinson’s [… targeted at outcomes
related to individual disease … well as specific groups of neurotransmitters that are of particular …

… Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of
dopaminergic neurons … and maintained their HR within the targeted range (Supplementary Fig. 1). …

… target in the prosaccade condition, or to look away from the … of neurotransmitter metabolites
and any exercise-induced … , although neither exercise mode had any significant effect on …

… phospholipids, deficits in neurotransmitter production, and compromised cellular signaling
pathways. Therefore, MQC is a target for PD treatment that is upstream of dopamine and α-…

… of striatal dopaminergic losses (estimated 30% attenuation of this relationship). Therefore,
nigrostriatal dopaminergic neurotransmission could serve as a potential intervention target to …

… neurotransmitters, dopamine delivers messages throughout the central nervous system (CNS)
[54]. Dopamine … They found 145 registered and ongoing clinical trials targeting PD spread …

… control neurotransmitters. However, pharmacological treatment with dopaminergic agonists
used in the management of PD symptoms was found to worsen the symptoms of sleeping …